Donald D Notman Jr plans 6,035-share sale in Ocular (NASDAQ: OCUL)

Rhea-AI Filing Summary

Ocular Therapeutix shareholder Donald D Notman Jr has filed a Form 144 notice to sell up to 6,035 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ around February 4, 2026. These 6,035 shares were acquired on February 3, 2026 through restricted stock vesting under a registered plan. The notice states that there were 213,047,472 common shares outstanding. The filing also reports that Notman previously sold 5,455 common shares on February 2, 2026 for gross proceeds of $49,872.88.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	6035	51540.71	213047472	02/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/03/2026	Restricted stock vesting under a registered plan	Issuer			6035	02/03/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
DONALD D NOTMAN JR. 15 Crosby Drive Bedford MA 01730	Common	02/02/2026	5455	49872.88

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the OCUL Form 144 filing by Donald D Notman Jr disclose?

The Form 144 filing shows that shareholder Donald D Notman Jr plans to sell up to 6,035 Ocular Therapeutix common shares. The notice identifies NASDAQ as the trading venue and Morgan Stanley Smith Barney LLC as the broker arranging the potential sale.

How many Ocular Therapeutix (OCUL) shares does the Form 144 cover and when were they acquired?

The Form 144 covers 6,035 Ocular Therapeutix common shares. These shares were acquired on February 3, 2026 through restricted stock vesting under a registered plan with the issuer, rather than through a cash purchase transaction in the open market.

What previous OCUL share sales by Donald D Notman Jr are reported in this Form 144?

The filing reports that Donald D Notman Jr sold 5,455 Ocular Therapeutix common shares on February 2, 2026. Those sales generated gross proceeds of $49,872.88, and are disclosed as securities sold during the three months prior to this notice.

Which broker and exchange are involved in the planned OCUL share sale in this Form 144?

The planned sale of 6,035 Ocular Therapeutix common shares is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing specifies NASDAQ as the securities exchange where the common stock is expected to be sold.

How many Ocular Therapeutix (OCUL) common shares were outstanding according to this Form 144?

The Form 144 states that 213,047,472 Ocular Therapeutix common shares were outstanding. This figure provides context for the size of the planned 6,035-share sale relative to the company’s total common stock base at the time of the notice.

What representation does the seller make about information on Ocular Therapeutix in this Form 144?

By signing the notice, the seller represents that they do not know any material adverse information about Ocular Therapeutix’s current or prospective operations that has not been publicly disclosed, consistent with Rule 144 requirements for sales of restricted or control securities.